sub:assertion {
d:DB00472 dv:ddi-interactor-in dr:DB00472_DB00543 .
d:DB00543 dv:ddi-interactor-in dr:DB00472_DB00543 .
dr:DB00472_DB00543 dcterms:identifier "drugbank_resource:DB00472_DB00543" ;
dcterms:title "DDI between Fluoxetine and Amoxapine - The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, amoxapine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of amoxapine if fluoxetine is initiated, discontinued or dose changed."@en ;
a dv:Drug-Drug-Interaction ;
rdfs:label "DDI between Fluoxetine and Amoxapine - The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, amoxapine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of amoxapine if fluoxetine is initiated, discontinued or dose changed. [drugbank_resource:DB00472_DB00543]"@en .
}